Used in the treatment of hypercholesterolemia and cardiovascular diseases by inhibiting PCSK9, a protein that reduces the liver's ability to remove low-density lipoprotein (LDL) cholesterol from the bloodstream. By blocking PCSK9, this antibody increases the number of LDL receptors on liver cells, significantly lowering circulating LDL cholesterol levels. It serves as a reference in the development of biosimilar and generic PCSK9 inhibitor therapies, supporting pharmaceutical research and regulatory testing. Also utilized in clinical diagnostics and biomarker studies to measure PCSK9 activity and therapeutic efficacy in lipid-lowering treatments.